ADC Therapeutics SA
ADCTStock
$1.35−63.28%52W
Market Cap$162.17M
P/E—
Div yield—
Beta1.84
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-73.93%
Price vs S&P 500 (4W)17.54%
VGM Score43.51
Market Capitalization$162.17M
Earnings Surprise History
Q1 26-0.13est. -0.22
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.33
4.33
4.33
3.83
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ADCTADC Therapeutics SA | C | C | F | $1.35 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
ADC Therapeutics is an oncology-focused biotechnology company with an FDA-approved product, ZYNLONTA, for relapsed or refractory large B-cell lymphoma. The company develops antibody-drug conjugates (ADCs) targeting hematological malignancies and solid tumors, supported by a pipeline of candidates across multiple mechanisms. Revenue is generated primarily from the United States and Europe.